Late Onset Vitamin B6 Dependent Epilepsy Identified by Rapid Genome Sequencing

A. Chris Espinoza MD, Melissa A. Wright MD, Meghan S. Candee MD, MS, Cristina Trandafir MD, PhD, Gary R. Nelson MD

1University of Utah Department of Pediatrics, Division of Pediatric Neurology, Salt Lake City, Utah

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.
Search Terms: Generalized Seizures (76), Status Epilepticus (297), All Genetics (91), Metabolic Disease inherited (153), All Pediatric (227)

Submission Type: Resident and Fellow Section – Child Neurology

Title Character Count: 78

Abstract Word Count: 187

Manuscript Word Count: 1516

Corresponding Author:
A. Chris Espinoza

Email: audie.espinoza@hsc.utah.edu

Study funding: No targeted funding reported.

Disclosure: The authors report no disclosures relevant to the manuscript.
Introduction: Hundreds of distinct epilepsy causing genes have been identified\(^1\). The vitamin B6 dependent epilepsies are a heterogeneous group of genetic disorders due to incomplete formation, transport, or inactivation of pyridoxal 5’-phosphate (PLP)\(^2\). The *ALDH7A1, PNPO, ALPL, ALDH4A1*, and more recently *PLPBP* genes have been implicated\(^3\). Characteristic presentation of vitamin B6 dependent epilepsies includes neonatal onset of encephalopathy and seizures refractory to first line anti-seizure medications (ASM) followed by cessation or dramatic improvement of seizures after administration of pyridoxine or PLP. Because initiation of proper treatment is essential for seizure control, timely diagnosis is critical to optimizing clinical outcome. We describe the case of a 3-year-old boy who presented with progressively worsening refractory seizures starting at 14 months of age, and was subsequently diagnosed with pyridoxal phosphate homeostasis protein (PLPHP) deficiency via rapid genome sequencing during a critical care hospitalization for status epilepticus. He was started on pyridoxine with immediate cessation of seizure activity and has remained seizure free. We review the diagnosis, management, and outcome of PLPHP deficiency, as well as implications for use of rapid genetic testing in the acute care setting.

Clinical Case: The patient was born at 39 weeks gestational age via an uncomplicated pregnancy and delivery. He was developmentally appropriate for age without significant medical or family history prior to his initial presentation at 14 months of age when he presented with new, prolonged and recurrent emotional and myoclonic seizures. On EEG, the interictal background was diffusely slow and disorganized with superimposed, high amplitude, synchronous bi-occipital, as well as generalized, sharp and spike discharges. Ictal recordings showed insidious increase in frequency of epileptiform discharges (1-2 Hz frequency), waxing and waning for prolonged periods of time (10-30 minutes), with unclear onset/offset (Figure 1A) and occasional
myoclonic jerks (Figure 1B). Clinically, the patient ran to his parents and appeared frightened, then became still with decreased responsiveness, occasionally followed by intermittent generalized myoclonic twitching, corresponding to generalized epileptiform discharges on EEG. After seizure onset, his speech regressed. At his initial presentation, he had a normal MRI brain. Laboratory diagnostic testing, including evaluation of routine CSF studies, metabolic studies (urine organic acids, plasma and CSF amino acids, CSF homovanillic acid, 3-O-methyldopa, and 5-hydroxyindoleacetic acid), paraneoplastic studies (urine vanillylmandelic/homovanilliac acid) etiologies, and CSF and serum autoimmune encephalitis antibody panels were normal with exception of mild hyperlactatemia. A comprehensive epilepsy gene panel showed variants of unknown significance in \textit{SCN2A}, \textit{IQSEC2}, and \textit{ABAT} genes. Levetiracetam, fosphenytoin, zonisamide, and benzodiazepines were trialed with continued breakthrough seizure clusters. His prolonged seizures resolved with phenobarbital loads and seizures stopped after initiation of topiramate and IVIG. He experienced seizure freedom for 6 months prior to returning with another period of frequent seizure clustering and onset of tonic clonic seizures as well. Repeat MRI brain at 22 months demonstrated bilateral mesial temporal sclerosis (Figure 2). He had frequent pediatric intensive care unit (PICU) admissions for super refractory status epilepticus responsive to phenobarbital and propofol. He was transitioned to valproic acid, clobazam, and lacosamide with resolution of his seizures. He was seizure free until 3 years of age, when he had four PICU admissions for super refractory status epilepticus, despite escalation in ASM dosing, over a three-month period. Parents noted more prominent regressions with each seizure cluster. With his most recent admission, he underwent multiple rounds of anesthetic drips including propofol, ketamine, and pentobarbital burst suppression. Rapid induction of the ketogenic diet was trialed, but stopped due to development of pancreatitis. IVIG and high dose IV steroid
courses were trialed with unclear efficacy. Rapid whole genome sequencing (rWGS) was obtained and revealed a compound heterozygous pathogenic variation of the *PLPBP* gene, formerly known as PROSC^4^, (maternal inheritance of c.260C>T variant and paternal inheritance of c.320-2A>G variant). Alpha aminoacidic semialdehyde (AASA) and pipecolic acid in serum and urine were normal. He was given a pyridoxine 100 mg IV trial and since has remained seizure free. Concurrent EEG monitoring with pyridoxine administration showed subtle increased amplitude and greater prominence of diffuse beta activity. At time of diagnosis, he was treated with 5 ASMs and at discharge successfully weaned his ASMs to clobazam, epidiolex, and pyridoxine 250 mg twice daily. After initiation of pyridoxine, he was more talkative and interactive.

**Discussion:**

**VITAMIN B6 DEPENDENT EPILEPSY**

Vitamin B6 dependent epilepsies were first described clinically in 1954 with the resolution of seizures in a neonate after administration of a multivitamin preparation^5^. Among genetic variants described, typical presentation consists of neonatal onset of medication resistant seizures which notably resolve with administration of high dose pyridoxine. *ALDH7A1* pathogenic variants, responsible for pyridoxine dependent epilepsy (PDE), has been the most extensively described vitamin B6 dependent epilepsy with greater than 200 cases identified. None of the patients reported had onset of seizures after 12 months of age^6^. Our patient presented with seizures at the age of 14 months and was ultimately diagnosed with PLPHP deficiency.

**PATHOGENESIS**
PLPHP deficiency is the most recently discovered pathogenic gene variant responsible for vitamin B6 dependent epilepsy with approximately 30 cases published thus far, all with onset of symptoms prior to 3 months of age\(^7\). PLPHP is responsible for intracellular homeostasis of PLP, an important enzymatic cofactor, particularly in the central nervous system. Enzyme activity of \(\gamma\)-aminobutyric acid (GABA) transaminase is reliant on PLP, thus disruptions in this pathway may be responsible for seizures\(^2\). Our patient had partial response to phenobarbital, a GABA mediated anti-seizure agent, which has been previously reported in PLPHP deficiency\(^4,7,8\). Based on previously reported cases and our patient’s experience, recurrent episodes of seizure clustering resistant to adjustments in ASMs and anesthetic drips separated by prolonged periods of seizure control may be a distinguishing hallmark of PLPHP deficiency. Focal seizures consisting of intense fear, hallucinations, and emotional lability are also unique features for PLPHP deficiency\(^2,8\).

DIAGNOSTICS

Other vitamin B6 dependent epilepsies such as PDE and pyridoxal-5’-phosphate dependent epilepsy have specific abnormal biomarkers (AASA and pipecolic acid) however, these biomarkers are typically normal in PLPHP deficiency. Interestingly, hyperlactatemia is a consistently reported biochemical abnormality in PLPHP deficiency\(^7\). EEG features in PLPHP deficiency vary from burst suppression pattern to normal. Nonspecific MRI abnormalities, such as microcephaly or under developed white matter, are common, although a large portion of patients have no structural abnormalities\(^2,4,9\). Normal metabolic screening and late onset of presentation were barriers to diagnosis in our patient.
TREATMENT

Our case illustrates the importance of a pyridoxine treatment trial in refractory epilepsy beyond the neonatal period. Typical pyridoxine trial dosage is 100 mg and if no response is seen, administration of up to 500 mg maximum may be trialed. EEG monitoring should also be obtained during pyridoxine challenge as abrupt resolution of seizures and depressed amplitudes can be indicative of treatment response. Our patient did not have electrocerebral depression with pyridoxine, although he has had complete resolution of seizures. Complications of high dose IV pyridoxine include cardiorespiratory depression, although this has infrequently been observed in patients with PLPHP deficiency. Maintenance dosing of pyridoxine ranges from 15-30 mg/kg/d (divided in two to three doses) with maximum daily dose of 200 mg and 500 mg in neonates and adults respectively. Long term use of high dose pyridoxine, especially at higher than recommended doses, may be complicated by sensory and rarely motor neuropathy. In PLPHP deficiency, complete seizure freedom with pyridoxine monotherapy is not the rule, and many patients require continued additional ASM therapy. If no response is seen with pyridoxine, a trial of PLP supplementation should be considered. Further studies are needed to determine if either pyridoxine or PLP supplementation is more efficacious for PLPHP deficiency.

PROGNOSIS

In vitamin B6 dependent epilepsies, breakthrough seizures are seen, particularly in setting of febrile illnesses, and some authors suggest management with transient increases in maintenance pyridoxine dosing. Despite early treatment with pyridoxine or PLP, developmental delay and cognitive impairment appear to be a common feature for PLPHP deficiency.
RAPID WHOLE GENOME SEQUENCING

rWGS is widely used in neonatal intensive care units and has been shown to be useful for timely clinical management and decision making. In addition to decreased morbidity and mortality, rWGS has been shown to reduce hospital cost\textsuperscript{10}. Sanford \textit{et al.} recently demonstrated use of rWGS in yielding clinically relevant diagnostic information which altered decision making in PICU settings as well\textsuperscript{10}. rWGS identified pathogenic variants with a turnaround time of 10 days in our patient. Use of rWGS allowed for targeted clinical management for our patient, avoidance of invasive neurosurgical procedures, and direct improvement in acute and long-term seizure control. In PLPHP deficiency, rWGS may be particularly advantageous as this disorder lacks conventional biomarkers for vitamin B6 dependent epilepsies and is not present on most commercial epilepsy gene panels.

Our case demonstrates that PLPHP deficiency is a rare, but treatable epileptic encephalopathy that may be missed via typical metabolic and genetic work ups. Although typical presentation of vitamin B6 dependent epilepsies are in the neonatal period, pyridoxine challenge should be considered in refractory epilepsy even if a patient’s initial presentation occurs beyond the neonatal or infancy periods. There is growing evidence that rWGS is a useful clinical tool in evaluating previously undiagnosed children in hospital and pediatric critical care settings.

\textbf{Appendix 1: Authors}

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Chris Espinoza, MD</td>
<td>University of Utah, Salt Lake City</td>
<td>Patient management, literature review, initial draft of the manuscript, preparation and final approval of manuscript</td>
</tr>
<tr>
<td>Melissa Wright, MD</td>
<td>University of Utah, Salt</td>
<td>Patient management,</td>
</tr>
<tr>
<td>Name</td>
<td>Institution</td>
<td>Role</td>
</tr>
<tr>
<td>-----------------------</td>
<td>------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Meghan S. Candee, MD, MS</td>
<td>Lake City</td>
<td>critical review of the manuscript, final approval of manuscript</td>
</tr>
<tr>
<td>Cristina Trandafir, MD</td>
<td>University of Utah, Salt Lake City</td>
<td>Patient management, critical review of the manuscript, final approval of manuscript</td>
</tr>
<tr>
<td>Gary R. Nelson MD</td>
<td>University of Utah, Salt Lake City</td>
<td>Patient management, critical review of the manuscript, final approval of manuscript</td>
</tr>
</tbody>
</table>

**Acknowledgements**: The authors thank the Primary Children’s Center for Personalized Medicine and Intermountain Precision Genomics for funding for rapid whole genome sequencing.
References


Figure 1A – Ictal EEG (Timebase 30mm/sec, Sensitivity 15uV/mm) showing subtle increase in frequency of bi-occipital spike and slow wave discharges. B– Ictal EEG (Timebase 30mm/sec, Sensitivity 15uV/mm). Generalized spike and wave discharge (associated with generalized myoclonic jerk) followed by diffuse fast activity for 1.5 seconds, then high amplitude delta slowing.
Figure 2 – Coronal T2 FLAIR MRI Brain – Bilateral mesial temporal sclerosis.